MedTrace Logo

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

NCT02321436 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-09-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate if early administration (i.e. within 12 weeks after stroke) of Dysport® 500 U injections may delay the appearance or the progression of upper limb symptomatic spasticity.

Conditions

  • Stroke
  • Upper Limb Spasticity

Interventions

BIOLOGICAL

Botulinum toxin type A

Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.

DRUG

Placebo

Placebo administered intramuscularly in the targeted upper limb.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Malaysia
  • Philippines
  • Singapore
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321436 on ClinicalTrials.gov